![Abin Thomas](https://profiles-cardiff.imgix.net/attachments/9772?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Abin Thomas
(he/him)
Teams and roles for Abin Thomas
Research Fellow (Statistics)
Overview
I am a Research Fellow in Statistics at the Centre for Trials Research at Cardiff University, where I work as a medical statistician. My role involves the design, conduct, analysis, and reporting of randomised controlled trials and other well-designed studies. I particularly focus on clinical trials in haematology and cancer, as well as research in perinatal health and other applied health areas.
My background is in biostatistics, and I have expertise in survival analysis, regression modelling, Bayesian methods, predictive modelling, and clinical trial methodology. I contribute to all stages of trial development and delivery, including protocol development, statistical analysis plans, reporting, publications, and grant applications. Additionally, I support the supervision and mentoring of junior statisticians and contribute to collaborative methodological research. Through my work, I aim to apply robust statistical methods to address important clinical questions and improve patient outcomes.
Publication
2026
- Mehta, P. et al., 2026. A randomized comparison of CPX-351 and FLAG-Ida in high-risk myelodysplastic syndrome: A subgroup analysis of UK NCRI AML19. Leukemia Research Reports 100609. (10.1016/j.lrr.2026.100609)
- Mehta, P. et al., 2026. CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial [Letter]. Leukemia & Lymphoma 67 (10), pp.2159-2163. (10.1080/10428194.2026.2690155)
- Knapper, S. et al. 2026. Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial. Blood (10.1182/blood.2025032681)
- Todd, S. et al., 2026. Procalcitonin testing combined with NEWS2 evaluation compared with usual care based on NEWS2 for identification of sepsis and antibiotic initiation in the emergency department in England and Wales (PRONTO): a multicentre, randomised, controlled, open-label, phase 3 trial. The Lancet Respiratory Medicine 14 (5), pp.417-431. (10.1016/S2213-2600(25)00433-3)
- Knapper, S. et al. 2026. CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18 trial. Blood 147 (10), pp.1048-1057. (10.1182/blood.2025031006)
2025
- Russell, N. H. et al., 2025. Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3 mutated AML. Blood Advances 9 (24), pp.6455-6466. (10.1182/bloodadvances.2025017244)
- Van Der Maas, N. G. et al., 2025. A revised prognostic model for patients with acute myeloid leukemia and first relapse. Blood Advances 9 (15), pp.3853-3864. (10.1182/bloodadvances.2025015797)
- Potter, N. et al., 2025. Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials. The Lancet Haematology 12 (5), pp.e346-e356. (10.1016/S2352-3026(25)00037-7)
- Russell, N. H. , Thomas, A. and Freeman, S. D. 2025. Reply to: Treatment intensification based on residual disease in elderly patients with AML. Journal of Clinical Oncology (10.1200/JCO-25-00198)
- Russell, N. H. et al., 2025. Treatment intensification with either fludarabine, AraC, G-CSF and idarubicin, or cladribine plus daunorubicin and AraC on the basis of residual disease status in older patients With AML: Results From the NCRI AML18 Trial. Journal of Clinical Oncology 43 (6), pp.694-704. (10.1200/JCO.24.00259)
- Aleem, A. et al., 2025. Discontinuation of tyrosine kinase inhibitor therapy and treatment free remission (TFR) in chronic myeloid leukemia: Successful achievement of TFR in more than two-third of patients in a real-world practice. Clinical Lymphoma, Myeloma and Leukemia 25 (1), pp.50-56. (10.1016/j.clml.2024.08.006)
2024
- Versluis, J. et al., 2024. Risk stratification in older intensively treated patients with AML. Journal of Clinical Oncology 42 (34), pp.4084-4094. (10.1200/JCO.23.02631)
2023
- Freeman, S. D. et al., 2023. Fractionated versus single dose Gemtuzumab Ozogamicin with determinants of benefit in older AML: UK NCRI AML18 Trial. Blood 142 (20), pp.1697-1707. (10.1182/blood.2023020630)
- Knapper, S. et al., 2023. S131: a randomised assessment of the sequential addition of the kinase inhibitor Quizartinib to intensive chemotherapy in older acute myeloid leukaemia (AML) patients: results from the NCRI AML18 trial [Abstract]. HemaSphere 7 , pp.69-70. e0819670. (10.1097/01.hs9.0000967436.08196.70)
- Potter, N. et al., 2023. P503: a randomised trial of molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 studies. HemaSphere 7 , pp.857-858. e345570d. (10.1097/01.hs9.0000968920.34557.0d)
2022
- Russell, N. H. et al., 2022. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukaemia: results of the NCRI acute myeloid leukemia 16 trial. Haematologica 107 (7), pp.1518-1527. (10.3324/haematol.2021.279010)
2021
- Tiong, I. S. et al., 2021. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Advances 5 (23), pp.5107-5111. (10.1182/bloodadvances.2021005455)
- Yousef, C. C. et al., 2021. Liraglutide effects on glycemic control and weight in patients with Type 2 Diabetes mellitus: a real-world, observational study and brief narrative review. Diabetes Research and Clinical Practice 177 108871. (10.1016/j.diabres.2021.108871)
- Nagraj, S. et al., 2021. Role of invasive mechanical ventilation and ECMO in the management of COVID-19: a systematic review. Indian Journal of Critical Care Medicine 25 (6), pp.691-698. (10.5005/jp-journals-10071-23870)
- AlAmmari, M. et al., 2021. The development and validation of a multivariable model to predict the bleeding risk score for patients with non-valvular atrial fibrillation using direct oral anticoagulants in the Arab population.. PLoS ONE 16 (5) e0250502. (10.1371/journal.pone.0250502)
- Esba, L. C. A. et al., 2021. Ibuprofen and NSAID use in COVID-19 infected patients is not associated with worse outcomes: a prospective cohort sudy. Infectious Diseases and Therapy 10 , pp.253-268. (10.1007/s40121-020-00363-w)
- Ammari, M. A. et al., 2021. Mental health outcomes amongst health care workers during COVID 19 pandemic in Saudi Arabia. Frontiers in Psychiatry 11 619540. (10.3389/fpsyt.2020.619540)
2020
- Tiong, I. S. et al., 2020. The natural history of NPM1MUT Measurable Residual Disease (MRD) positivity after completion of chemotherapy in Acute Myeloid Leukemia (AML). Presented at: 62nd American Society of Hematology Annual Meeting & Exposition (ASH 2020) Virtual 5-8 December 2020. Vol. 136.Vol. Supple. American Society of Hematology. , pp.25-27. (10.1182/blood-2020-140296)
- Yousef, C. C. et al., 2020. Adoption of a personal health record in the digital age: Cross-sectional study. Journal of Medical Internet Research 22 (10) e22913. (10.2196/22913)
2019
- Alaskar, A. et al., 2019. Chemotherapy effect on fertility in male patients with Hodgkin and Non-Hodgkin Lymphoma. Presented at: 61st American Society of Hematology Annual Meeting & Exposition (ASH 2019) Orlando, FL, USA 07-10 December 2019. Vol. 134.Vol. S1. American Society of Hematology. , pp.5865. (10.1182/blood-2019-126447)
- Shaheeen, N. A. et al., 2019. Reducing defects in the datasets of clinical research studies: conformance with data quality metrics. BMC Medical Research Methodology 19 98. (10.1186/s12874-019-0735-7)
- Alotaibi, B. et al., 2019. Tuberculosis knowledge, attitude and practice among healthcare workers during the 2016 Hajj. PLoS ONE 14 (1) e0210913. (10.1371/journal.pone.0210913)
- Shaheen, N. A. et al., 2019. Paternal postnatal depression among fathers of newborn in Saudi Arabia. American Journal of Men's Health 13 (1), pp.1-12. (10.1177/1557988319831219)
Articles
- Mehta, P. et al., 2026. A randomized comparison of CPX-351 and FLAG-Ida in high-risk myelodysplastic syndrome: A subgroup analysis of UK NCRI AML19. Leukemia Research Reports 100609. (10.1016/j.lrr.2026.100609)
- Mehta, P. et al., 2026. CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial [Letter]. Leukemia & Lymphoma 67 (10), pp.2159-2163. (10.1080/10428194.2026.2690155)
- Knapper, S. et al. 2026. Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial. Blood (10.1182/blood.2025032681)
- Todd, S. et al., 2026. Procalcitonin testing combined with NEWS2 evaluation compared with usual care based on NEWS2 for identification of sepsis and antibiotic initiation in the emergency department in England and Wales (PRONTO): a multicentre, randomised, controlled, open-label, phase 3 trial. The Lancet Respiratory Medicine 14 (5), pp.417-431. (10.1016/S2213-2600(25)00433-3)
- Knapper, S. et al. 2026. CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18 trial. Blood 147 (10), pp.1048-1057. (10.1182/blood.2025031006)
- Russell, N. H. et al., 2025. Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3 mutated AML. Blood Advances 9 (24), pp.6455-6466. (10.1182/bloodadvances.2025017244)
- Van Der Maas, N. G. et al., 2025. A revised prognostic model for patients with acute myeloid leukemia and first relapse. Blood Advances 9 (15), pp.3853-3864. (10.1182/bloodadvances.2025015797)
- Potter, N. et al., 2025. Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials. The Lancet Haematology 12 (5), pp.e346-e356. (10.1016/S2352-3026(25)00037-7)
- Russell, N. H. , Thomas, A. and Freeman, S. D. 2025. Reply to: Treatment intensification based on residual disease in elderly patients with AML. Journal of Clinical Oncology (10.1200/JCO-25-00198)
- Russell, N. H. et al., 2025. Treatment intensification with either fludarabine, AraC, G-CSF and idarubicin, or cladribine plus daunorubicin and AraC on the basis of residual disease status in older patients With AML: Results From the NCRI AML18 Trial. Journal of Clinical Oncology 43 (6), pp.694-704. (10.1200/JCO.24.00259)
- Aleem, A. et al., 2025. Discontinuation of tyrosine kinase inhibitor therapy and treatment free remission (TFR) in chronic myeloid leukemia: Successful achievement of TFR in more than two-third of patients in a real-world practice. Clinical Lymphoma, Myeloma and Leukemia 25 (1), pp.50-56. (10.1016/j.clml.2024.08.006)
- Versluis, J. et al., 2024. Risk stratification in older intensively treated patients with AML. Journal of Clinical Oncology 42 (34), pp.4084-4094. (10.1200/JCO.23.02631)
- Freeman, S. D. et al., 2023. Fractionated versus single dose Gemtuzumab Ozogamicin with determinants of benefit in older AML: UK NCRI AML18 Trial. Blood 142 (20), pp.1697-1707. (10.1182/blood.2023020630)
- Knapper, S. et al., 2023. S131: a randomised assessment of the sequential addition of the kinase inhibitor Quizartinib to intensive chemotherapy in older acute myeloid leukaemia (AML) patients: results from the NCRI AML18 trial [Abstract]. HemaSphere 7 , pp.69-70. e0819670. (10.1097/01.hs9.0000967436.08196.70)
- Potter, N. et al., 2023. P503: a randomised trial of molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 studies. HemaSphere 7 , pp.857-858. e345570d. (10.1097/01.hs9.0000968920.34557.0d)
- Russell, N. H. et al., 2022. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukaemia: results of the NCRI acute myeloid leukemia 16 trial. Haematologica 107 (7), pp.1518-1527. (10.3324/haematol.2021.279010)
- Tiong, I. S. et al., 2021. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Advances 5 (23), pp.5107-5111. (10.1182/bloodadvances.2021005455)
- Yousef, C. C. et al., 2021. Liraglutide effects on glycemic control and weight in patients with Type 2 Diabetes mellitus: a real-world, observational study and brief narrative review. Diabetes Research and Clinical Practice 177 108871. (10.1016/j.diabres.2021.108871)
- Nagraj, S. et al., 2021. Role of invasive mechanical ventilation and ECMO in the management of COVID-19: a systematic review. Indian Journal of Critical Care Medicine 25 (6), pp.691-698. (10.5005/jp-journals-10071-23870)
- AlAmmari, M. et al., 2021. The development and validation of a multivariable model to predict the bleeding risk score for patients with non-valvular atrial fibrillation using direct oral anticoagulants in the Arab population.. PLoS ONE 16 (5) e0250502. (10.1371/journal.pone.0250502)
- Esba, L. C. A. et al., 2021. Ibuprofen and NSAID use in COVID-19 infected patients is not associated with worse outcomes: a prospective cohort sudy. Infectious Diseases and Therapy 10 , pp.253-268. (10.1007/s40121-020-00363-w)
- Ammari, M. A. et al., 2021. Mental health outcomes amongst health care workers during COVID 19 pandemic in Saudi Arabia. Frontiers in Psychiatry 11 619540. (10.3389/fpsyt.2020.619540)
- Yousef, C. C. et al., 2020. Adoption of a personal health record in the digital age: Cross-sectional study. Journal of Medical Internet Research 22 (10) e22913. (10.2196/22913)
- Shaheeen, N. A. et al., 2019. Reducing defects in the datasets of clinical research studies: conformance with data quality metrics. BMC Medical Research Methodology 19 98. (10.1186/s12874-019-0735-7)
- Alotaibi, B. et al., 2019. Tuberculosis knowledge, attitude and practice among healthcare workers during the 2016 Hajj. PLoS ONE 14 (1) e0210913. (10.1371/journal.pone.0210913)
- Shaheen, N. A. et al., 2019. Paternal postnatal depression among fathers of newborn in Saudi Arabia. American Journal of Men's Health 13 (1), pp.1-12. (10.1177/1557988319831219)
Conferences
- Tiong, I. S. et al., 2020. The natural history of NPM1MUT Measurable Residual Disease (MRD) positivity after completion of chemotherapy in Acute Myeloid Leukemia (AML). Presented at: 62nd American Society of Hematology Annual Meeting & Exposition (ASH 2020) Virtual 5-8 December 2020. Vol. 136.Vol. Supple. American Society of Hematology. , pp.25-27. (10.1182/blood-2020-140296)
- Alaskar, A. et al., 2019. Chemotherapy effect on fertility in male patients with Hodgkin and Non-Hodgkin Lymphoma. Presented at: 61st American Society of Hematology Annual Meeting & Exposition (ASH 2019) Orlando, FL, USA 07-10 December 2019. Vol. 134.Vol. S1. American Society of Hematology. , pp.5865. (10.1182/blood-2019-126447)